Propel Bio Management, LLC Phathom Pharmaceuticals, Inc. Transaction History
Propel Bio Management, LLC
- $86.1 Billion
- Q1 2025
A detailed history of Propel Bio Management, LLC transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Propel Bio Management, LLC holds 1,134,927 shares of PHAT stock, worth $9.85 Million. This represents 8.27% of its overall portfolio holdings.
Number of Shares
1,134,927
Previous 989,927
14.65%
Holding current value
$9.85 Million
Previous $8.04 Billion
11.47%
% of portfolio
8.27%
Previous 7.98%
Shares
4 transactions
Others Institutions Holding PHAT
# of Institutions
142Shares Held
59.2MCall Options Held
94KPut Options Held
55.5K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$87.7 Million3.99% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$64.8 Million20.28% of portfolio
-
Invesco Ltd. Atlanta, GA3.65MShares$31.7 Million0.0% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$30.4 Million27.15% of portfolio
-
Black Rock Inc. New York, NY2.93MShares$25.4 Million0.0% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $340M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...